ROR1 靶向治疗市场：目标表达谱、药物模式安全性和有效性、管道审查和竞争格局分析

本报告研究了 ROR1 靶向治疗市场，并提供了市场概况以及临床趋势、适应症和患者趋势、竞争格局以及进入市场的公司概况。

内容

常用缩写

第 0 章执行摘要

第一章目标背景：结构与功能

第 2 章目标抗原表达谱

• 血液系统恶性肿瘤
• 各种实体瘤
• 肺癌
• 胰腺癌
• 结肠癌
• 乳腺癌
• 卵巢癌

第 3 章 ROR1 靶向候选药物的临床前安全性

第 4 章 ROR1 靶向药物治疗的临床经验

第5章临床适应症和患者人群

• 慢性淋巴细胞白血病
• 套细胞淋巴瘤
• 瀰漫性大 B 细胞淋巴瘤
• 三阴性乳腺癌

第 6 章竞争格局和药物模式

• ROR1 靶向抗体-药物偶联物
• T 细胞结合抗 ROR1 抗体
• ROR1 靶向 CAR T 细胞和 NK 细胞的过继性细胞疗法
• ROR1小分子抑製剂

第 7 章药物和细胞疗法候选者简介

• 裸抗体
• 抗体药物偶联物
• 涉及 T 细胞的双特异性抗体
• CART 细胞和 NK 细胞
• 小分子抑製剂

第 8 章公司简介

第 9 章参考文献

This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as a tumor-specific target for cancer therapy based on its expression profile and preclinical and clinical safety and efficacy data of the various drug modalities employed for discovery and development of ROR1-targeted therapy candidates.

The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field. The report includes information about business transaction in the field, such as acquisitions, partnerships & collaborations and licensing deals. Furthermore, the financial background and situation of the key players is described.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type I transmembrane protein that is physiologically expressed in early embryogenesis and plays a critical role in organogenesis. Expression of ROR1 attenuates rapidly after embryonic development, becoming virtually undetectable on post-partem tissues, with the exception of a few B cell precursors. In contrast, ROR1 is expressed on a variety of cancers, particularly those that are less differentiated, and is associated with early relapse after therapy or metastasis.

Because of its tumor-specific expression and potential functional significance, ROR1 has become of interest as a target for various drug modalities, especially with enhanced effector function. The most advanced molecules is currently being evaluated in potentially registrational phase II/III studies, but the majority of programs are in late preclinical and early clinical development, thus still offering opportunities for improvements.

This report is based information retrieved from proprietary database, clinical trial registries, abstracts, presentations and posters from scientific meetings as well as full publications, from company websites, press releases, SEC filings, investor and R&D presentations. The report was prepared in May/June of 2022 and was released on June 16, 2022.

What will you find in the report:

• The scientific rationale for ROR1-targeted therapies based on target characteristics and its differential expression profile;

• Preclinical safety of ROR1-targeted therapy candidates;

• Clinical experience and proof-of-concept with ROR1-targeted drug modalities;

• Clinical indications suitable for development of ROR1-targeted therapies and their patient populations;

• The competitive landscape of ROR1-targeted drug modalities in development;

• Specific profiles of ROR1-targeted drug modalities; and

• Profiles of companies active in the development of anti-ROR1 therapy candidates.

Table of Contents

Frequent Abbreviations

0. Executive Summary

1. Target Background: Structure & Function

2. Target Antigen Expression Profile

• 2.1. Hematologic Malignancies
• 2.2. Various Solid Tumors
• 2.3. Lung Cancer
• 2.4. Pancreatic Cancer
• 2.5. Colorectal Cancer
• 2.6. Breast Cancer
• 2.7. Ovarian Cancer

3. Preclinical Safety of ROR1-Targeted Therapy Candidates

4. Clinical Experience with ROR1-Targeted Drug Modalities

5. Clinical Indications & Patient Populations

• 5.1. Chronic Lymphocytic Leukemia
• 5.2. Mantle Cell Lymphoma
• 5.3. Diffuse Large B-Cell Lymphoma
• 5.4. Triple Negative Breast Cancer

6. Competitive Landscape & Drug Modalities

• 6.1. ROR1-Targeted Antibody Drug Conjugates
• 6.2. T-Cell EngagingAnti-ROR1 Antibodies
• 6.3. Adoptive Cell Therapy with ROR1-Targeted CAR T-Cells and NK Cells
• 6.4. ROR1 Small Molecule Inhibitor

7. Drug & Cell Therapy Candidate Profiles

• 7.1. Naked Antibody
• 7.2. Antibody-Drug Conjugates
• 7.3. T-Cell Engaging Bispecific Antibodies
• 7.4. CAR T-Cells & NK Cells
• 7.5. Small Molecule Inhibitor

8. Company Profiles

9. References

List of Tables

• Table 1: Overview of the Number of Cases of ROR1 Overexpression in Hematologic Malignancies
• Table 2: Overview of the Number of Cases of ROR1 Overexpression in Solid Tumors
• Table 3: Lead and Up-Side Indications of Clinical Studies with ROR1-Targeted Therapy Candidates
• Table 4: Overview of Number and R&D Stage of ROR1-Targeted Drug Modalities
• Table 5: Pipeline of ROR1-Targeted Antibody-Drug Conjugates in Development
• Table 6: Pipeline of T-Cell Engaging ROR1-Targeted Antibodies
• Table 7: Pipeline of ROR1-Targeted CAR T-Cells and NK Cells
• Table 8: NovalGen's ROR1-Targeted Drug Modality Pipeline